Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
IMMUNOMEDICS (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 4 out of 4 possible stars; its market behaviour has improved and can be considered as moderately risky. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date September 18, 2020, the closing pri...
Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020 Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors Conference call and webcast with key opinion leaders on September 19, 2020 MORRIS PLAINS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the presentation of five abstracts at ESMO Virtual Congress 2020, highlighted by o...
Immunomedics to Participate in Upcoming Healthcare Conferences MORRIS PLAINS, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences: 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9 at 8:40 a.m. Eastern Time Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Tuesday, September 15 a...
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™ Approval enhances long-term supply of Trodelvy MORRIS PLAINS, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Samsung Biologics to produce commercial-scale hRS7, the antibody used in Trodelvy (sacituzumab govitecan-hziy), at its manufacturing facilities...
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update Encouraging early adoption of Trodelvy™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key secondary endpoints of overall survival and objective response rate Full ASCENT results will be submitted to ESMO Virtual Congress 2020 as late-breaking abstract Supplemental Biologics License Application seeking full approval of Trodelvy anticipated to be submitted to FDA in fourth quarter 2020 MORRIS PLAINS, N.J., Aug....
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020 MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2020 and provide a corporate update. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 988777...
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant triple-negative breast cancer has begun patient enrollment MORRIS PLAINS, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates ...
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC) Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed Trodelvy is the first antibody-drug conjugate (ADC) shown to improve clinical outcomes in people with relapsed or refractory mTNBC who have received t...
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update MORRIS PLAINS, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will host a conference call and live audio webcast on Monday, July 6, 2020 at 8:00 a.m. Eastern Time to provide a clinical update. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 8872919. The conference call will be webcast via the I...
Immunomedics to Participate in Upcoming Healthcare Conferences MORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences: Jefferies Virtual Healthcare Conference on Thursday, June 4 at 3:30 p.m. Eastern Time Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9 at 9:40 a.m. Eastern Time Live...
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19 Harout Semerjian steps down from his role as CEO MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update on a leadership change as well as the Company’s efforts to navigate through the ongoing coronavirus pandemic. The Company announces that, after careful consideration, Harout Semerjian has decided to step down from his role as President and Ch...
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its recently FDA-approved ADC, Trodelvy, showed clinical activity in cisplatin-ineligible patients with metastatic urothelial cancer (mUC) and in patients with previously-treated metastatic endometrial cancer (mEC). “These early-stage study data highlight the potential broa...
Immunomedics to Participate in BofA Securities 2020 Health Care Conference MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 2:20 p.m. Eastern Time. Live audio webcast of the fireside chat will be accessible and available for replay from the Company’s website at ....
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study stopped early due to compelling evidence of efficacy across multiple endpoints, topline results around mid-2020 MORRIS PLAINS, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today reported finan...
Upside Momentum Lost, But Not Breaking Down Uptrends from the March lows were violated late last week for the S&P 500, Nasdaq, and Dow. Additionally, the S&P 500 failed to break above the 61.8% Fibonacci retracement level of 2934.49, while the Nasdaq and Dow also stalled at key resistance levels. This tells us that recent highs are likely to represent a near-term top. As we outlined in last week's Compass, our base case was for some near-term consolidation while the market is in a “wait-and-s...
Immunomedics Announces Commercial Availability of TRODELVY™ in the United States MORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major specialty distributors in the United States and that the first patient was treated with commercial product on April 29, 2020. Trodelvy is the first anti-Trop-2 ADC recently approved by the U.S. Food and Drug Administration (FDA) for th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.